Today, Kimberly-Clark announced it will acquire Kenvue, the maker of Tylenol, for $48.7 billion, forming one of the largest consumer health companies in the United States valued at $32 billion.
After the transaction closes, current Kimberly-Clark shareholders are expected to hold about 54% of the combined company on a fully diluted basis, while current Kenvue shareholders are expected to hold 46%.
Mike Hsu, Kimberly-Clark Chairman and CEO told investors, “We are excited to bring together two iconic companies to create a global health and wellness leader. Kenvue is uniquely positioned at the intersection of CPG and healthcare, with exceptional talent and a differentiated brand offering serving attractive consumer health categories. With a shared commitment to developing science and technology to provide extraordinary care, we will serve billions of consumers across every stage of life.”
“Over the last several years, Kimberly-Clark has undertaken a significant transformation to pivot our portfolio to higher-growth, higher-margin businesses while rewiring our organization to work smarter and faster. We have built the foundation and this transaction is a powerful next step in our journey. We look forward to working with the Kenvue team to bring these companies together, and are confident that we will drive significant value for our combined shareholders,” continued Hsu.
Kirk Perry, CEO of Kenvue, stated, “Our combination with Kimberly-Clark unites two highly complementary portfolios filled with iconic, beloved brands and everyday essentials that people trust and count on throughout their lives. Our teams share a passion for delivering science-backed solutions that play a meaningful role in homes and communities around the world. Together, our combined strengths, expanded capabilities and resources, and broader reach will empower us to innovate even faster and strengthen our category leadership.”
The transaction is anticipated to close in the second half of 2026.
Following the announcement, Kenvue’s shares rose 18% in premarket trading, while Kimberly-Clark’s shares declined 12.5%.
By CEO NA Editorial Staff
